SCHEMBL1069153

SCHEMBL1069153

CN(Cc1ccc(OCc2ccccc2F)cc1)C(C(N)=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.57
LPAR1 Q92633 3/20 0.54
LPAR5 Q9H1C0 3/20 0.54
MAOB P27338 5/20 0.53
PARP15 Q460N3 2/20 0.53
PARP10 Q53GL7 2/20 0.53
PARP14 Q460N5 1/20 0.53
SCN3A Q9NY46 6/20 0.52
PTPN1 P18031 1/20 0.48
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
KCNH2 Q12809 3/20 0.46
SCN1A P35498 1/20 0.43
SCN4A P35499 1/20 0.43
SCN7A Q01118 1/20 0.43
SCN5A Q14524 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN8A Q9UQD0 1/20 0.43
SCN10A Q9Y5Y9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1070268 0.83 MAOB (0.58) SCN9AMAOBPARP10
SCHEMBL5681599 0.80 NPY5R (0.49) PARP10
SCHEMBL5680325 0.80 NPY5R (0.49) PARP10
SCHEMBL5681607 0.80 NPY5R (0.49) PARP10
SCHEMBL4192667 0.78 EPHX1 (0.49) KCNH2
SCHEMBL27601267 0.78 EPHX1 (0.49) KCNH2
Hydrochloric Acid SCHEMBL4208521 0.77 EPHX1 (0.47) KCNH2
SCHEMBL1071565 0.76 SCN9A (0.73) SCN9ALPAR1LPAR5MAOBPARP15
SCHEMBL5684462 0.76 NR3C1 (0.45) LPAR1LPAR5MAOB
SCHEMBL5695719 0.76 NR3C1 (0.45) LPAR1LPAR5MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2977046-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS Newron Pharmaceuticals S.p.A. (IT) 2016-01-27 EP claimed
US-8741957-B2 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders NEWRON PHARMACEUTICALS S.P.A. (IT) 2014-06-03 US claimed
US-8697738-B2 Alpha-aminoamide derivatives useful in the treatment of addictive disorders NEWRON PHARMACEUTICALS S.P.A. (IT) 2014-04-15 US claimed
US-20130217747-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME NEWRON PHARM SPA (US) 2013-08-22 US claimed
EP-2343064-A1 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders Newron Pharmaceuticals S.p.A. (IT) 2011-07-13 EP claimed
EP-1900362-B1 Alfa-aminoamide derivatives useful in the treatment of addictive disorders NEWRON PHARM SPA (IT) 2011-01-12 EP claimed
EP-1658062-B1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS NEWRON PHARM SPA (IT) 2010-02-17 EP claimed
US-20100016437-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-01-21 US claimed
US-20100016440-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS NEWRON PHARMACEUTICALS S.P.A. (IT) 2010-01-21 US claimed
EP-2029130-A2 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS Newron Pharmaceuticals S.p.A. (IT) 2009-03-04 EP claimed
EP-1870097-A1 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders Newron Pharmaceuticals S.p.A. (IT) 2007-12-26 EP claimed
WO-2007144153-A2 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-12-21 WO claimed
US-20070276046-A1 Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-11-29 US claimed
US-20070203182-A1 Alpha-Aminoamide Derivatives Useful In The Treatment Of Restless Legs Syndrome And Addictive Disorders NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-08-30 US claimed
EP-1737438-A1 alpha-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS Newron Pharmaceuticals S.p.A. (IT) 2007-01-03 EP claimed
EP-1658062-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS Newron Pharmaceuticals S.p.A. (IT) 2006-05-24 EP claimed
WO-2005102300-A1 α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS NEWRON PHARMACEUTICALS S.P.A. (IT) 2005-11-03 WO claimed
EP-1588704-A1 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders Newron Pharmaceuticals S.p.A. (IT) 2005-10-26 EP claimed
EP-1557166-A1 Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders Newron Pharmaceuticals S.p.A. (IT) 2005-07-27 EP claimed
WO-2005018627-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS NEWRON PHARMACEUTICALS, SPA (IT) 2005-03-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016437-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS PSEN1, MAPT, AADAT SCN9A 3223/4885LPAR1 1870/4885LPAR5 1150/4885
US-20100016440-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS IL1A, AADAT, DNPEP SCN9A 2253/4885LPAR1 2585/4885LPAR5 2642/4885
US-20070203182-A1 Alpha-Aminoamide Derivatives Useful In The Treatment Of Restless Legs Syndrome And Addictive Disorders PNMT, AADAT, BCAT2 SCN9A 963/4885LPAR1 570/4885LPAR5 510/4885
US-20130217747-A1 ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AADAT, PNMT, BCAT2 SCN9A 946/4885LPAR1 503/4885LPAR5 468/4885
US-20070276046-A1 Alpha-Aminoamide Derivatives Useful as Anti-Inflammatory Agents IL1A, AADAT, DNPEP SCN9A 2253/4885LPAR1 2585/4885LPAR5 2642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.